SAG
OVID icon

SageView Advisory Group’s Ovid Therapeutics OVID Stock Holding History

SageView Advisory Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44
Closed -$72 – 1859
2025
Q4 		$72 Buy
+44
New +$68 ﹤0.01% 2556

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

SageView Advisory Group's OVID Position: Q1 2026 in Review

SageView Advisory Group sold out of Ovid Therapeutics (OVID) in Q1 2026, closing a stake of 44 shares — an estimated $72 sold.

SageView Advisory Group first reported a position in OVID in Q4 2025 and held it in 1 quarter. The position peaked at $72 in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • SageView Advisory Group reported no remaining Ovid Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 44 Ovid Therapeutics shares in Q1 2026, an estimated $72.
  • SageView Advisory Group first reported a position in Ovid Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Ovid Therapeutics position peaked at $72 in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.